<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04982055</url>
  </required_header>
  <id_info>
    <org_study_id>IV vs SC LMWH ICU</org_study_id>
    <nct_id>NCT04982055</nct_id>
  </id_info>
  <brief_title>Intravenous Versus Subcutaneous Administration of Low Molecular Weight Heparin for Thromboprophylaxis in Critically Ill Patients</brief_title>
  <official_title>Intravenous Versus Subcutaneous Administration of Low Molecular Weight Heparin for Thromboprophylaxis in Critically Ill Patients: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinique Saint Pierre Ottignies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinique Saint Pierre Ottignies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To compare the pharmacokinetic profiles of intravenous versus subcutaneous route&#xD;
      of administration of LMWH for thromboprophylaxis in critically ill patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective, monocentric, randomized trial. Patients are randomized to the IV&#xD;
      route of administration over a 4-hours infusion of nadroparin 3800 IU or to the SC route of&#xD;
      administration. Randomization is stratified according to the need for vasopressor or not.&#xD;
      Anti-Xa activity is measured at baseline, and at 1, 2, 4, 6, 8, 12 and 24 hours after the&#xD;
      administration was started.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 8, 2015</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak anti-Xa activity</measure>
    <time_frame>Peak anti-Xa activity obtained 4 hours after start of low molecular weight heparin administration</time_frame>
    <description>Peak anti-Xa activity obtained 4 hours after start of low molecular weight heparin administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough anti-Xa activity</measure>
    <time_frame>Trough anti-Xa activity measured 24 hours after start of low molecular weight administration</time_frame>
    <description>Trough anti-Xa activity measured 24 hours after start of low molecular weight administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-24h)</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Area under the curve 0-24 hours of anti-Xa activity after start of low molecular weight heparin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Intravenous group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcutaneous group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nadroparin (intravenous Infusion)</intervention_name>
    <description>Intravenous route of administration over a 4-hours infusion of nadroparin 3800 IU</description>
    <arm_group_label>Intravenous group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nadroparin (subcutaneous group)</intervention_name>
    <description>Subcutaneous route of administration of nadroparin 3800 IU</description>
    <arm_group_label>Subcutaneous group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults patients &gt; 18 years old admitted in the ICU, and for whom thromboprophylaxis is&#xD;
             indicated&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  renal failure determined by glomerular filtration rate (GFR) &lt; 30 ml/min or need for&#xD;
             renal replacement therapy&#xD;
&#xD;
          -  liver cirrhosis&#xD;
&#xD;
          -  intravascular disseminated coagulation&#xD;
&#xD;
          -  contra-indication to thromboprophylaxis for any reason as decided by the treating&#xD;
             physician, or indication for therapeutic dosing anticoagulation (recent&#xD;
             thrombo-embolic event, atrial fibrillation,…)&#xD;
&#xD;
          -  patients receiving low dose of vasopressor (norepinephrine &lt; 0.25 mcg/kg/min) to allow&#xD;
             stratification and comparison between patients not on vasopressors and patients with a&#xD;
             significant dose of vasopressors (norepinephrine ≥ 0.25 mcg/kg/min)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 8, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinique Saint Pierre Ottignies</investigator_affiliation>
    <investigator_full_name>Nicolas De Schryver</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nadroparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

